World leaders in andrology call on governments to prioritise male reproductive health 'for the health and survival of our species'

After more than 20 years of study and debate, the controversies surrounding aneuploidy testing in embryos continues. At the heart of a recent exchange of opinion is the effect of mosaicism on results.

Balancing the clinical benefits in miscarriage risk against the non-benefits in cumulative live birth rate.

ESTEEM trial co-ordinating investigator Willem Verpoest believes there are important benefits - and messages - to be found in this ESHRE study of aneuploidy screening

Shoukhrat Mitalipov’s group has finally hit back at critics who disputed the interpretation of experiments in which a potentially fatal genetic mutation was corrected in human embryos. Sofia Makieva reports.

Minutes of the Annual Assembly of Members, held on Tuesday 3 July 2018, 18.00 pm, at Centre de Convencions de Barcelona, Plaça de Willy Brandt 11-14, 08019 Barcelona, Spain

Cristine Magli, an investigator in the ESHRE-sponsored ESTEEM trial, explains more on the design of the study and why the results provide strong evidence about PGT-A.

A prediction calculator for cumulative live birth in IVF based on the UK's HFEA database has been validated in an external independent cohort of IVF patients.

For the first time, a large population study quantifies the effect of cancer and its treatment on the chances of pregnancy.

Karen Sermon, principal investigator of the ESTEEM trial, reviews the results and implications of this ESHRE-sponsored study of aneuploidy screening.